Pegaspargase
Clinical data
Pronunciation/pəˈɡæspərɡz/
Trade namesOncaspar
AHFS/Drugs.comMonograph
MedlinePlusa695031
License data
Pregnancy
category
  • AU: D
Routes of
administration
Intramuscular, intravenous
ATC code
Legal status
Legal status
Identifiers
  • Pegylated E. coli L-asparagine amidohydrolase
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC1377H2208N382O442S17
Molar mass31732.06 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Pegaspargase, sold under the brand name Oncaspar, is a medication used in the treatment of acute lymphoblastic leukemia (ALL).[2] Often it is used together with anthracycline, vincristine, and prednisone.[3] It is used by injection.[3]

Common side effects include allergic reactions, blood clotting problems, high blood sugar, liver problems, pancreas inflammation, and blood clots in the brain.[3] Its use during pregnancy may harm the baby.[4] It is a modified version of the enzyme asparaginase which has undergone PEGylation.[5][3] It works by breaking down asparagine, decreasing its availability to make protein.[3]

Pegaspargase was approved for medical use in the United States in 1994.[3] It is on the World Health Organization's List of Essential Medicines.[6] It is made by Sigma-Tau.[3]

References

  1. ^ "Oncaspar EPAR". European Medicines Agency (EMA). Retrieved 21 January 2021.
  2. ^ Graham ML (2003). "Pegaspargase: a review of clinical studies". Adv. Drug Deliv. Rev. 55 (10): 1293–302. doi:10.1016/S0169-409X(03)00110-8. PMID 14499708.
  3. ^ a b c d e f g "Pegaspargase Monograph for Professionals". Drugs.com. Retrieved 11 October 2019.
  4. ^ "Pegaspargase (Oncaspar) Use During Pregnancy". Drugs.com. Retrieved 11 October 2019.
  5. ^ "UNM Cancer Center". Archived from the original on 3 September 2006. Retrieved 28 August 2007.
  6. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.